Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Short interest dropped by over 1,054,000 shares in the past two weeks, and by almost 2.5MM shares in the past 4 weeks. Games have been played here for years!
SETTLEMENT DATE SHORT INTEREST AVG. DAILY SHARE VOLUME DAYS TO COVER
11/15/2019 706,163 3,533,420 1
10/31/2019 1,760,589 3,577,832 1
10/15/2019 3,193,668 15,227,951 1
Wow...
Expected a follow through, and none occurred. Same old, same old pump and dump. Some things never change, and you can count on Advaxis to be a Stradivarius in the hand of the hedge funds. This is the sucker's game.
From the Notice of Delisting:
Sabby Management a new owner -- not a good sign. Sigh...
SABBY MANAGEMENT, LLC 1,521,982 0.11 49 1,480,260 8.8385% 13F 2019-09-30 2019-11-15
Sorry, but Altium is an old news -- they have filed their stake of 1.7MM shares on 7/23/19 during the previous 13F report cycle. They haven't filed the new form yet, and I would not be surprised to see if the sold out.
The new reports show that Renaissance Technologies increased their position by almost 1.5MM shares to 1.98MM shares. Acadian is another fund that made a new stake by purchasing 365K shares. Not so good sign is that Private Advisor Group shows 100K shares. Why? They are very aggressive traders, mostly they short. Need to see if they have Puts and Calls.
Another misconception is that Edelman's presence here was a good sign -- he might have been a very large short here. That's his nature.
RENAISSANCE TECHNOLOGIES LLC 1,979,786 0.00 2855 1,478,786 11.4970% 13F 2019-09-30 2019-11-13
ACADIAN ASSET MANAGEMENT LLC 365,051 1497 365,051 2.1199% 13F 2019-09-30 2019-11-07
PRIVATE ADVISOR GROUP, LLC 100,798 1623 100,798 0.5854% 13F 2019-09-30 2019-11-13
“Those that think this is a scam company”
———————————
Those are longer around here. We believe in the great future of Advaxis! Just around several corners ! We are the patients of this great company that will cure investors! Once and for ever!
Bye-Bye-Bye!
I doubt either Edelman or Adage lost money in Advaxis although they declared they were long in the stock and were supposed to lose their shirt here. Most likely, they had multiple accounts for different subsidiaries and they shorted the hell of this equity while "publicly" being long. That's the way it works now with these hedgies. Both likely made lots of money here.
As they say in Germanistan: “Und?”
I'm so much excited about the recent stock options issued to our high performing management team! Ken definitely more than deserved his 50,000 new shares for his hard work at leading this company from the best place to work in NJ to a best place to work in the world!
I see this as a sign of future success of this company, and I remain tremendously excited about the progress we are going to see in 2047!
Remember when the management said:” we are here to cure cancer”, did they say they’d be curing the cancer in mice? I think they had meant just that, not in human.
PS. I’m tired of setting the mouse traps while I get no help from AXAL.
# nomoremicecancercures
Next thing on the chopping block is ADXS-PSA.
They have been unable to partner it, MRK is not impressed with the data. Thus, the obvious outcome here is to shut that PSA program down. Not sure why it's still "active" and draining very tight resources. Ken need to face the inevitable and pull the plug on the trial. The longer he waits, the more cash burn gets.
Same old, same old... Call me unimpressed.
Advaxis Announces Business and Pipeline Update
https://finance.yahoo.com/news/advaxis-announces-business-pipeline-130000658.html
PRINCETON, N.J.--(BUSINESS WIRE)--
Cash balance anticipated to extend into 2021
Advaxis, Inc. (ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the following updates to its clinical programs.
ADXS-HOT: Cancer Type-Focused Hotspot/Off-the-Shelf Neoantigen-Directed Therapies – The ADXS-HOT program is a cancer-type specific immunotherapy that targets hotspot mutations, cancer testis antigens and oncofetal antigens. The first drug candidate from this program, ADXS-503, is designed to target most types of non-small cell lung cancer (NSCLC) and is currently being evaluated in a Phase 1/2 clinical trial, enrolling patients at five sites. The first dose level with monotherapy in Part A, (1 X108 CFU) has been completed and the Part A-second dose level (5 X108 CFU) and Part B in combination with a checkpoint inhibitor are currently open to enrollment. The Company plans to report immune response data from Part A monotherapy by the end of 2019.
Advaxis intends to file an investigational new drug (IND) application for its ADXS-504 (HOT Prostate) program by the end of 2019 and has completed manufacturing of its ADXS-506 (HOT Bladder) construct, enabling the construct to enter clinical development in the future.
ADXS-NEO: Personalized, Neoantigen-Directed Therapy – ADXS-NEO is a personalized neoantigen-directed immunotherapy designed to activate a patient’s immune system in a range of cancers. The company has enrolled its last patient in Part A, the monotherapy portion of its Phase 1 dose-escalation study, which was planned to be followed by Part B, dose escalation in combination with a checkpoint inhibitor. Data previously released on the ADXS-NEO program demonstrated the tolerability, to date, of this construct at 1 X108 CFU and indicated signals of a robust anti-tumor immune response. Additionally, the signals of anti-tumor immune responses included a strong CD8+ T cell reactivity generated against personalized as well as hotspot mutations, which provided valuable insight for the company’s HOT constructs. As the company moves into the combination arm of its HOT NSCLC study, it has determined that the information gained from the HOT NSCLC study will provide an opportunity to demonstrate the effects of its neoantigen constructs used in combination with a checkpoint inhibitor, thereby minimizing the benefits of entering Part B of the ADXS-NEO study. Therefore, the company has elected to not continue into Part B of the ADXS-NEO study in combination with a checkpoint inhibitor. The company plans to continue to dose the last patient enrolled in Part A in accordance with the protocol and cease further enrollment. The company intends to publish the final results from Part A of the ADXS-NEO study at a future medical meeting and close its ADXS-NEO program IND thereafter.
ADXS-PSA: Prostate Cancer – The company recently reported updated data for its Phase 1/2 KEYNOTE-046 study of ADXS-PSA, alone and in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for unselected and advanced patients with metastatic castration-resistant prostate cancer (“mCRPC”).
The median overall survival for this patient population in the combination arm was 33.6 months (95% CI, range 15.4-33.6 months). These results are encouraging as the patient population in the combination arm (n=37) had high Gleason scores (9), MSI-high negative status, visceral metastatsis in 30%, prior chemotherapy in 57% and one to two prior next generation hormonal agents in >80% of patients. The company is in discussions with potential partners regarding opportunities to expand or advance this mCRPC program.
ADXS-HPV: Axalimogene filolisbac (AXAL):
- Cervical Cancer – As announced in July, the company is in the process of winding down its Phase 3 AIM2CERV study evaluating AXAL for the treatment of patients with high-risk, locally advanced cervical cancer. As a result of the closure of this study, the company will be unblinding the data and anticipates reporting the results of the 110 patients that had been dosed with AXAL in this study by the end of 2019.
- Lung Cancer –Global BioPharma, Inc. (GBP), the company’s partner in certain Asian and African territories, anticipates initiating its Phase 2, open-label controlled trial in HPV-associated NSCLC in patients following first-line chemotherapy by the end of 2019. The study will be assessing the effects of AXAL when combined with pemetrexed in patients with HPV+ NSCLC, following first line induction therapy.
“At Advaxis, we are committed to unlocking the potential benefits of our Lm TechnologyTM platform to improve outcomes for cancer patients,” said Kenneth A. Berlin, President and Chief Executive Officer of Advaxis. “The NEO trial has provided us with valuable proof-of-mechanism data for our HOT program, with clinical signals of generation of CD8+ T cells against hotspot mutations, antigen spreading and stable disease in two patients. While discontinuing the NEO program was a difficult decision, we ultimately believe that the off-the-shelf approach of our HOT program will allow us to more effectively evaluate our platform in a broad patient population with a more economical, commercial-ready manufacturing process while also extending our cash runway until early 2021. I want to personally thank the patients, employees and collaborating physicians who participated in or assisted with this study.” He concluded, “The strength of our technology and pipeline leave us well positioned to explore a variety of strategic opportunities heading into 2020.”
About Advaxis, Inc.
Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.
To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially include: the impact of the discontinuation on relationships related to the AIM2CERV Study; the success and timing of our clinical trials, including subject accrual; our ability to avoid and quickly resolve any clinical holds; our ability to obtain and maintain regulatory approval and/or reimbursement of our product candidates for marketing; our ability to obtain the appropriate labeling of our products under any regulatory approval; our plans to develop and commercialize our products; the successful development and implementation of our sales and marketing campaigns; the size and growth of the potential markets for our product candidates and our ability to serve those markets; our ability to successfully compete in the potential markets for our product candidates, if commercialized; regulatory developments in the United States and other countries; the rate and degree of market acceptance of any of our product candidates; new products, product candidates or new uses for existing products or technologies introduced or announced by our competitors and the timing of these introductions or announcements; market conditions in the pharmaceutical and biotechnology sectors; our available cash, including to support current and planned clinical activities; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; our ability to obtain additional funding; our ability to obtain and maintain intellectual property protection for our product candidates; the success and timing of our preclinical studies including IND-enabling studies; the timing of our IND submissions; our ability to get FDA approval for study amendments; the timing of data read-outs; the ability of our product candidates to successfully perform in clinical trials; our ability to initiate, enroll, and execute pilots and clinical trials; our ability to maintain our existing collaborations; our ability to manufacture and the performance of third-party manufacturers; the performance of our clinical research organizations, clinical trial sponsors and clinical trial investigators; our ability to successfully implement our strategy; and, other risk factors identified from time to time in our reports filed with the SEC. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191024005253/en/
Well, refresh our dull memory, please: when was last time they delivered on their own promises?
Pipeline update is as obscure term as it gets. Remember "term sheets", "inflection point", "curing cancer", and etc. They are gone as the past year's snow. New snow fall is coming, so now it's pipeline update. It could be as big as an inclusion of a paying partner into Slide 2 of the corporate presentation once the stock reaches $10. Or, it could be a subtle inclusion of something like "X number of patients demonstrated an 0.45% increase in theta-gamma-intergalactic sub-protein levels after ..." which could trigger another round of sell offs. So, we don't know what's coming, but our history indicates it's the latter.
I suspect that the management wanted to do another secondary using these last news releases. However insane that might sound they likely thought (and think) they need money now despite several disastrous raises in the last year. I have no other explanation for the series of the last soft PRs. They used to do that way before: start releasing some fluff PRs, and then follow up with killer secondaries. We might not done with the press releases, we might see one more press release tomorrow morning and then a raise after the close or within a day or two. Who knows. This stream of releases is very suspicious, but what’s new in Advaxistan.
I have googled him, looked at his CV, and his affiliation. That gave me an impression that he does not have any internal funds to support this collaboration. I could be wrong, but take your time and go through his resume. He lists every single step of his career, any conference paper or presentation, and he somehow fails to include references to his grants, awards for his projects? That’s not how it works. Everyone lists their achievements including funded projects from NIH and etc.
Also, he’s not tenured yet, and link to his lab at Cedars Sinai hospital doesn’t return anything. When you go through the list of faculty there and research labs, he’s not there. How that gives you any confidence that this collaboration is funded by UCLA or CS.
It’s on Advaxis, and it’s our money. Pathetic.
I can only post once a day, so no response until tomorrow
I was really puzzled about the collaboration that ADXS and Vaithi Arumugaswami's lab announced yesterday. Several points:
1) UCLA's Vaithi Arumugaswami has no background or expertise in GBM. Look at his CV, lab profile and see that he's a veterinarian, completed his PhD cell biology and worked on ZIKA virus.
https://bio.csmc.edu/view/14998/Vaithilingaraja-Arumugaswami.aspx
2) The funding of this "collab" is going to be an issue. Obviously, Arumugaswami has no internal funding for this project, and the pre-clinical work will likely be funded by ADXS once again. Instead of being laser focused on HOT and NEO, they now started this glioblastoma exploration? Did we just forget they canned several clinical programs (Aim2Cerv included) to save cash? Now they want to through good money after some decades away project? What the heck that is supposed to mean?
No surprise the stock cratered yesterday. In addition to a bull trap orchestrated masterfully by a fund or two, they got help from the ADXS management. Two PRs within few days and we now go back to low 20s. Looks like to cash deal is coming anytime soon.
Short interest over the top (4.6x increase from the last report):
SETTLEMENT DATE : SHORT INTEREST : AVG. DAILY SHARE VOLUME : DAYS TO COVER
09/30/2019 : 1,084,947 : 10,292,155 : 1
09/13/2019 : 235,594 : 2,001,983 : 1
Whoever runs the show, wanted to take this stock above 0.50 to short. They did not have enough firepower to rally despite massive number of troops sent to message outlets, and then the decision was likely to take what they could get -- short in low 0.40s and now we are going to see a massive drop to low 20s. Wash, rinse, repeat.
Unless you expect to live 158 more years, there's no way you can even partially recoup these losses. However, if it's the IRA money then it's lost (ahem, someone else cashed in on our future).
An update:
https://finance.yahoo.com/news/advaxis-announces-updated-prolonged-survival-120000418.html
Advaxis Announces Updated Prolonged Survival Data in Phase 1/2 ADXS-PSA Trial
RINCETON, N.J.--(BUSINESS WIRE)--
Median overall survival for ADXS-PSA in combination with KEYTRUDA® increased to 33.6 months from previously reported 21.1 months
Advaxis, Inc. (ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced updated median overall survival data from its Phase 1/2 KEYNOTE-046 study in metastatic, castration-resistant prostate cancer (mCRPC). This trial is being conducted in conjunction with Merck (known as MSD outside the U.S. and Canada) and is evaluating ADXS-PSA, one of Advaxis’ Listeria monocytogenes (Lm)-based immunotherapies, alone and in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.
At the final data cutoff of September 16, 2019, median overall survival for 37 patients in the combination arm was 33.6 months (95% CI, range 15.4-33.6 months). This updated median overall survival is an increase from the previous data presented at the American Association for Cancer Research (AACR) Annual Meeting in April, where median overall survival was 21.1 months in the combination arm. These new data, along with additional details from this final predetermined look at the trial results, will be presented at an upcoming medical conference.
“We are excited to report these updated data which show a meaningful increase in median overall survival for patients in the combination arm of the KEYNOTE-046 study,” said Kenneth A. Berlin, President and Chief Executive Officer of Advaxis. “We believe that ADXS-PSA in combination with KEYTRUDA® has the potential to be an important new treatment option for patients with advanced metastatic, castration-resistant prostate cancer, which based on these data, warrants further evaluation. We are currently assessing next steps for a potential new study for ADXS-PSA in combination with KEYTRUDA® in mCRPC and we look forward to providing additional details about the program’s path forward.”
Mark N. Stein M.D., FACS, Associate Professor of Medical Oncology at Columbia University Medical Center and lead investigator of the study, said, “Patients with metastatic castration-resistant prostate cancer who have failed next generation hormonal agents and/or docetaxel have limited treatment options. The updated survival data in a patient population with advanced prostate cancer suggests this generally well tolerated vaccine should be evaluated in larger studies. I look forward to the continued evaluation of ADXS-PSA in combination with KEYTRUDA® as a potential new treatment regimen that can improve patient outcomes while preserving quality of life.”
KEYNOTE-046 is an open-label, multicenter, dose-determining safety and tolerability Phase 1/2 trial of 50 heavily pretreated patients conducted in two parts (Part A and Part B), with a Phase 2 expansion cohort. The objective of the study is to evaluate ADXS-PSA alone (Part A) and in combination with KEYTRUDA® (Part B) for primary endpoints that include safety, tolerability and dosing. Secondary endpoints include anti-tumor activity, progression-free survival and overall survival, and exploratory endpoints that include associations between biomarkers of immunologic response (serum PSA) with clinical outcomes. Enrollment in the study has been completed. The majority of treatment-related adverse events consisted of transient and reversible Grade 1-2 chills/rigors, fever, hypotension, nausea and fatigue. The combination of ADXS-PSA and KEYTRUDA® has appeared to be well-tolerated, to date, with no additive toxicity observed.
About KEYNOTE-046
KEYNOTE-046 (NCT02325557) is a Phase 1/2 open-label, multicenter, dose-determination and expansion trial that evaluates the safety, tolerability and preliminary clinical activity of ADXS-PSA as monotherapy (Part A; n=14 [13 treated]), and in combination with KEYTRUDA® (Part B; n= 37) in heavily pretreated patients with progressive and refractory mCRPC.
About Advaxis, Inc.
Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors. Advaxis has three programs in various stages of clinical development: ADXS-NEO, a personalized neoantigen-directed therapy designed, in principle, for any solid tumor; ADXS-503 for non-small cell lung cancer, from its ADXS-HOT off-the-shelf neoantigen-directed program and ADXS-PSA for prostate cancer.
Nothing new, yawn...
Enrollment is very slow, unbelievable.
I could not believe my eyes: 48MM shares? WTF? Really?
Still no partners.
Would not be surprised if they do another reverse split soon and then go private after another raise.
Vicious cycle of destruction to continue.
Terry,
The enrollment has been glacial at best for NEO and likely for HOT. With the things are progressing at Advaxis, the best shot to see the next batch of clinical data is either AACR or ASCO in 2020.
As for the prostate combo data, we have no idea what's going on there. The management has been mum about the future of this trial, and I'm really puzzled by the lack of any progress there. Why MRK is not jumping and partnering with ADXS if the data is good, as we were told? I'm afraid the management will just put this program into a back-burner and let it disappear from screens. That's what they have done with other programs that consumed tens of millions of dollars with nothing to show for.
As I said here, I had contacted two law firms to look into a possible fraud investigation of ADXS former and current management. Sad to say, this has not advanced beyond an inquiry stage. Also, I have not seen any ambulance chasers jumping in. Why?
I recall that some here also intended to solicit a legal advice. If you did, can you share if you made any progress? I'd like to join this possible shareholders-vs-ADXS law suit, and try to get something back. This management should not go unpunished.
If Advaxis had anything to showcase, ESMO 2019 would have been the perfect forum to do so (9/27-10/1). They used to go there and present the data, last time 2 years ago. Nothing this time.
There will not any other major conference until April ‘20 (AACR and then ASCO). That’s too far out. No catalyst until then as it appears.
Ha, did you check the cockpit? it's empty. The crew has abandoned the plane few moments ago. Being prepared and knowing how to deploy your golden parachute make huge difference -- the passengers can now use oxygen masks before the plane hits the ground shortly...
Is that an immaculate cake eating process?
Who’s the other one?
It's classic -- they run up yesterday to short at higher prices, and then short and cover today. Why not? Wash, rinse, repeat ...
PS. When they say that the volume precedes the price, they did not specify the price direction. And definitely did not mean Advaxis...
There's Chapter 7 before we reach Chapter 11.
Hovacre has left this board a while ago, then removed himself from the moderators list, and likely will not return here.
He was cautious about ADXS, and when this house of cards collapsed he might have made a decision to get out. Sometimes things don't work out the way we want.
Awesome productivity:
from the last 10-Q:
Those could have the Advaxis shorts with a boat load of cash. Never mind it was the 14th century AD. They knew DOC would be on their side.
I have always had a paraskevidekatriaphobia, however, the recent Advaxis SEC filings do not scare me any longer whether they are filed on a regular day or Friday 13th. There is nothing to be scared of something that doesn’t exist. RIP, Advaxis.
Paraskevidekatriaphobia (Friday the thirteen phobia)
Paraskevidekatriaphobia is the fear of Friday the 13th. It is closely associated with triskaidekaphobia, but it is believed more people suffer from it. There is no reference suggesting that Friday the 13th was considered unlucky before the 19th century.
Just curious -- are we going to be in the teens before b.liu is back in 2 weeks or in single digits?
PS. it's cents, not dollars... unless another mega-RS happens soon.
Another quarterly report -- very impressive, LOL!
https://ir.advaxis.com/press-release/business-development/advaxis-reports-fiscal-third-quarter-2019-financial-results-and
Yes, something has been in the works for over three years. You won’t like it when you see it.
You guys still are having fun kicking the dead horse?
Can’t be any deader...
ADXS market cap is at $6MM -- that's 1/12th of Ken's annual salary. It's a shame that Ken issued a "get lost" letter and did not bother to cut his bloated salary, even by a penny.